Hohimer Wealth Management LLC Sells 1,256 Shares of United Therapeutics Corporation $UTHR

Hohimer Wealth Management LLC trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 9.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,370 shares of the biotechnology company’s stock after selling 1,256 shares during the quarter. Hohimer Wealth Management LLC’s holdings in United Therapeutics were worth $4,766,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. AXQ Capital LP raised its stake in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares during the last quarter. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its holdings in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in United Therapeutics during the 3rd quarter worth $444,000. Finally, Simplify Asset Management Inc. acquired a new position in United Therapeutics during the 3rd quarter worth about $8,351,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $503.60 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The stock has a 50 day simple moving average of $484.64 and a two-hundred day simple moving average of $444.51. The company has a market cap of $21.68 billion, a P/E ratio of 18.05, a PEG ratio of 2.85 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the firm posted $6.19 EPS. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 14,440 shares of United Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total value of $6,817,557.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $476.34, for a total transaction of $3,953,622.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $17,520,261.54. This represents a 18.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 407,954 shares of company stock worth $197,601,528. 10.30% of the stock is currently owned by company insiders.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. TD Cowen increased their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company upped their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $533.55.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.